
|Articles|October 1, 2002
Tazarotene indications may soon expand
Los Angeles - Already approved for the treatment of acne, tazarotene (Tazorac) is being investigated for the treatment of facial photodamage and clogged pores. The FDA is expected to grant regulatory approval for tazarotene to treat photodamaged facial skin within a few months.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
JAK Inhibitors Show Comparable Safety to TNF Antagonists
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
4
Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 1
5


















